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Abstract
Background:  Idiopathic  pulmonary  ﬁbrosis  has  a  median  survival  time  after  diagnosis  of  2--5
years. The  main  goal  of  treating  IPF  is  to  stabilize  or  reduce  the  rate  of  disease  progression.
Nintedanib and  Pirfenidone  have  been  a  breakthrough  in  the  management  of  IPF.  Here  we  eval-
uated the  effectiveness  of  Pirfenidone  and  Nintedanib  in  a  population  of  IPF  patients  diagnosed
in the  last  12  months  at  Florence  ILD  Referral  Centre.
Methods:  In  the  last  12  months,  82  IPF  patients  (66  male,  mean  age  78.3  ±  23.8  years)  were
diagnosed and  started  antiﬁbrotic  therapy  with  Pirfenidone  or  Nintedanib.  Their  clinical  and
functional  details  were  analyzed  retrospectively  at  time  0  and  after  6  and  12  months  of  therapy.
Results: The  median  age  of  the  patients  treated  with  Nintedanib  was  higher  than  that  of  the
Pirfenidone group  (p  <  0.0001).  The  most  common  symptoms  at  disease  onset  were  exertional
dyspnoea  and  dry  cough  with  no  differences  between  the  two  groups  (p  <  0.05).  All  IPF  patients
manifested  bibasal  crackles  at  the  time  of  diagnosis.  No  signiﬁcant  differences  in  FVC,  FEV1,
TLC and  DLCO  were  found  at  time  0  or  after  6  months  between  patients  treated  with  Pirfenidone
and Nintedanib  (p  >  0.05).  After  1  year,  lung  function  test  parameters  of  patients  treated  with
Pirfenidone  had  remained  stable  from  baseline.
Discussion:  This  study  emphasizes  that  both  antiﬁbrotic  drugs  appeared  to  be  a  good  therapeu-
tic choice  in  terms  of  functional  stabilization,  also  in  older  patients.
Published  by  Elsevier  España,  S.L.U.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Please  cite  this  article  in  press  as:  Bargagli  E,  et  al.  Pulmonol.
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bin  >1.5× ULN,  high  risk  of  bleeding,  INR  >2,  PT,  PTT  >150%
of  ULN,  major  surgery  scheduled  in  the  next  3  months  or
high  risk  of  thrombosis.  Pirfenidone  inclusion  criteria  in  Italy
were:  age  40--80  years,  IPF  diagnosed  in  past  48  months,ARTICLEULMOE-46; No. of Pages 5
 
ntroduction
diopathic  pulmonary  ﬁbrosis  (IPF)  is  a  chronic  progressive
nterstitial  lung  disease  (ILD)  of  unknown  aetiology,  limited
o  the  lungs,  and  characterized  by  a  usual  interstitial  pneu-
onia  (UIP)  histopathological  pattern.1,2 IPF  accounts  for
pproximately  55%  of  all  idiopathic  interstitial  pneumonias
IIP)  and  25%  of  all  interstitial  lung  diseases  (ILD)  with  about
5,000  new  diagnoses  per  year  in  Europe  and  5  million  in  the
orld.3 It  has  an  annual  incidence  of  0.22--7.4  per  100,000
ersons  and  a  prevalence  of  1.25--23.4  cases  per  100,000  of
opulation  and  is  more  frequent  in  patients  between  65  and
9  years  of  age.3 It  is  a  disabling  and  fatal  disease  with  a  poor
rognosis.1--11 Five-year  survival  is  20--40%,  which  is  lower
han  for  breast  cancer,  colorectal  cancer  and  pulmonary
rterial  hypertension.1--5 Because  there  is  no  known  cure,
he  goal  of  IPF  treatment  is  to  stabilize  or  reduce  the  rate  of
isease  progression.6 Two  therapies  for  IPF,  Nintedanib  and
irfenidone,  were  recently  approved  by  EMA  respectively  in
 .  .. . . and  FDA  4  years  ago.  The  new  drugs  have  been  a  break-
hrough  in  the  management  of  IPF.6 The  world-wide  phase  III
linical  trials  ASCEND,  CAPACITY  004  and  006  demonstrated
or  the  ﬁrst  time  that  Pirfenidone  reduced  IPF  progression
nd  brought  long-term  beneﬁts  to  these  patients.6--10 The
SCEND  trial  assessed  Pirfenidone  efﬁcacy  after  52  weeks,
hile  the  CAPACITY  study  determined  the  effects  of  the  drug
ver  an  observation  period  of  72  weeks.8 These  trials  found
hat  Pirfenidone  treatment  signiﬁcantly  reduced  the  decline
n  forced  vital  capacity,  improving  the  6-min  walking  test
istance  (6MWD)  by  50  m.7 In  addition,  progression-free  sur-
ival  analysis  showed  that  the  risk  of  IPF  progression  fell
y  38%  in  the  Pirfenidone  group  compared  to  the  placebo-
roup.  The  risk  of  IPF  mortality  during  treatment  declined
y  60%  in  the  group  of  patients  treated  with  Pirfenidone,
ompared  to  the  placebo  group,  while  the  risk  of  mortal-
ty  for  all  causes  fell  by  37%.10 Likewise,  phase  II  and  III
linical  trials  revealed  that  Nintedanib  slowed  progression
f  the  disease,  reducing  the  decline  in  FVC,12,13 while  the
OMORROW  study  showed  a  68%  reduction  in  annual  FVC
ecline  rate  for  Nintedanib-treated  patients  compared  to
 placebo  group  and  a  reduction  in  the  number  of  acute
xacerbations  in  treated  compared  to  untreated  patients.
he  INPULSIS  I  and  II  studies  consistently  demonstrated
he  efﬁcacy  of  Nintedanib  in  reducing  disease  progression
ith  a  signiﬁcant  slowing  down  in  the  annual  decline  in
VC.12,13 The  Italian  Medicines  Agency  AIFA  approved  Pir-
enidone  for  use  in  Italy  in  June  2013,  while  Nintedanib
as  authorized  in  April  2016.  Regional  Referral  Centres
or  ILD  can  prescribe  these  therapies  for  patients  with
PF.
In  the  present  study  we  evaluated  the  effectiveness  of
irfenidone  and  Nintedanib  in  a  population  of  patients  fol-
owed  at  our  hospital  last  year.  The  clinical  and  functional
haracteristics  of  IPF  patients  treated  with  Pirfenidone  or
intedanib  were  recorded  at  the  start  (time  0)  and  after  6
nd  12  months  of  treatment  to  deﬁne  the  effectiveness  of
ntiﬁbrotic  therapy  and  compare  it  with  data  in  the  litera-
ure.Please  cite  this  article  in  press  as:  Bargagli  E,  et  al.  Pulmonol. PRESS
E.  Bargagli  et  al.
opulation and methods
n  the  last  12  months,  82  IPF  patients  (66  male,  mean
ge  78.3  ±  23.8  years)  have  been  diagnosed  with  intersti-
ial  lung  diseases  (ILD)  at  AOUC  Careggi  Referral  Centre  and
tarted  antiﬁbrotic  therapy  with  Pirfenidone  or  Nintedanib.
he  clinical  and  functional  details  were  analyzed  ret-
ospectively  from  demographic  data,  family  history  for
ulmonary  ﬁbrosis,  smoking,  occupational/environmental
xposure  and  comorbidities.  The  following  parameters  were
ecorded:  age,  sex,  BAL  differential  cell  count,  BAL  lympho-
yte  phenotype,  lung  function  tests,  oxygen  desaturation
uring  6  min  walking  test,  and  PaO2 values  measured  by
lood  gas  analysis.  All  these  parameters  were  entered  in
 database  together  with  functional,  radiological,  histologi-
al  and  immunological  data.  Lung  function  test  parameters
ere  performed  according  to  ATS/ERS  guidelines  collecting
ercent  predicted  FEV1,  FVC,  TLC  and  DLCO.14 IPF  diagno-
is  was  based  on  clinical  radiological  parameters  in  70/82
PF  patients.  Chest  X-rays  in  the  posterior-anterior  and  lat-
ral  projections  and  high-resolution  computed  tomography
f  the  chest  were  done  in  all  patients.  Diagnosis  was  formu-
ated  in  the  context  of  a  multidisciplinary  meeting.
Histological  diagnosis  of  IPF/UIP  was  obtained  in  12
atients  with  HRCT  signs  of  IPF  with  no  clear  radiologi-
al  honeycombing;  four  patients  underwent  transbronchial
ung  cryobiopsy,  a  single  patient  underwent  non-intubated
horacic  surgery  performed  under  spontaneous  ventilation
AWAKE  VATS)  and  seven  patients  a  VATS  lung  biopsy.
In  a  subgroup  of  patients  bronchoscopy  with  bronchoalve-
lar  lavage  was  performed  with  informed  consent  of  patients
n  order  to  exclude  other  interstitial  lung  diseases.  Brieﬂy,
amples  were  obtained  by  instillation  of  four  aliquots  of
0  ml  saline  solution  by  videoﬁberoptic  bronchoscope.  Each
liquot  was  immediately  gently  aspirated.  The  ﬁrst  BAL
ample  was  kept  separate  from  the  others  and  was  not
sed  for  immunological  tests.  Sub-samples  were  cultured  for
icrobes,  fungi  and  viruses  to  exclude  infections.  Cells  were
eparated  by  centrifuge  and  the  ﬂuid  fraction  was  frozen
or  enzyme  assays.  Differential  cell  counts  were  done.  Lym-
hocyte  phenotype  was  analyzed  by  ﬂow  cytometry  using
nti-CD3,  CD4  and  CD8  monoclonal  antibodies.
The  patients  included  in  the  study  had  not  been  treated
ith  steroids  or  other  immunosuppressants  at  the  time  of
AL.  They  were  monitored  every  3  months  from  onset  at
ur  regional  interstitial  lung  disease  referral  centre.  All  gave
ritten  informed  consent  to  participation  in  the  study.
Patients  with  IPF  were  treated  with  Pirfenidone  or
intedanib  according  to  Italian  national  drug  inclu-
ion/exclusion  criteria.  Nintedanib  inclusion  criteria  in  Italy
ere  age  ≥40  years,  diagnosis  of  idiopathic  pulmonary
brosis  according  to  international  guidelines,  FVC  >50%  of
redicted  and  DLCO  >30%.  Exclusion  criteria  for  Nintedanib
reatment  in  Italy  were  ALT,  AST  >1.5× ULN,  total  biliru- 2018.  https://doi.org/10.1016/j.pulmoe.2018.06.003
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Table  1  Clinical  features  of  IPF  patients  treated  with  Pir-
fenidone  (n  =  52)  or  Nintedanib  (n  =  30).
Pirfenidone
(n  =  52)
Nintedanib
(n  =  30)
Age  (M  ±  SD)  71.0  ±  6.1  78.3  ±  5.5**
Male 81%  (42/52)  80%  (24/30)
Dyspnoea  81%  (42/52)  85%  (25/30)
Bibasal crackles  100%  100%
Dry cough  83.9  ±  32.6  85.8  ±  37.2
Bal Tot  cells  (×104)  12.5  ±  11.8  13.6  ±  12.9
Macrophages  (%) 69.1  ±  29.3 68  ±  31.2
Lymphocytes  (%) 18.3  ±  10.5 17.4  ±  11.1
Neutrophils  (%) 8.5  ±  7.4 8.5  ±  8
Eosinophils  (%)  5.9  ±  4.8  6.2  ±  4.6
PaO2 (mmHg)  70.6  ±  38.1  68.4  ±  49.9
PaCO2 (mmHg) 29.3  ±  11  28.6  ±  18.7
Oxygen  desaturation  6MWT 55%  (29/52)  63%  (19/30)
No signiﬁcant differences were found between the two groups,
except that mean age was signiﬁcantly higher in the Nintedanib
than the Pirfenidone group (**p  < 0.001).
BAL = bronchoalveolar lavage, M = macrophages,
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Figure  1  Males  and  females  in  the  populations  of  Pirfenidone
(81%) versus  Nintedanib  (80%).
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Figure  2  Average  values  of  FVC,  FEV1,  TLC  and  DLCO  per-
centages  of  predicted  at  time  0  (n  =  52),  after  6  months  (n  =  35)
and 12  months  (n  =  25)  in  patients  treated  with  Pirfenidone.
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8L = lymphocytes, N = neutrophils, E = eosinophils. The results are
reported as medium ± standard deviation.
FVC  ≥50%  of  theoretical  value  and  DLCO  ≥35%  of  predicted
value.  Exclusion  criteria  for  Pirfenidone  treatment  were
hypersensitivity  to  the  active  substance  or  to  any  of  the
excipients,  severe  liver  function  or  liver  disease  in  terminal
stage,  severe  renal  impairment  (CrCl  <30  ml/min)  or  kid-
ney  disease  in  terminal  stage  requiring  dialysis.  When  the
patients  fulﬁlled  criteria  for  use  of  both  drugs  (Nintedanib
and  Pirfenidone)  the  ﬁnal  decision  was  based  on  contraindi-
cations  and  patient  choice  when  faced  with  the  different
side-effect  proﬁles.  A  relevant  aspect  was  the  dosage  (Pir-
fenidone  is  administered  as  three  capsules  taken  three  times
a  day,  whereas  Nintedanib  only  one  capsule  twice  a  day).
All  the  clinical,  radiological,  immunological  parameters
were  entered  in  a  database  and  updated  every  3  months
during  clinical  assessment.
Statistical  analysis
All  data  was  expressed  as  mean  ±  standard  deviation.  The
Wilcoxon  test  was  used  to  describe  the  trend  of  PFR  patients
in  the  two  treatment  groups.  Analysis  of  variance  (with  Bon-
ferroni  test  for  internal  comparisons)  was  used  to  compare
groups.  Statistical  signiﬁcance  was  set  at  p  <  0.05.  Statisti-
cal  analysis  was  carried  out  using  StatSoft  (2001)  and  Graph
Pad  Prism  software.
Results
Table  1  shows  the  clinical  characteristics  of  82  IPF  patients
enrolled  in  this  study  in  the  last  12  months:  52  patients  were
treated  with  Pirfenidone  and  30  patients  with  Nintedanib.Please  cite  this  article  in  press  as:  Bargagli  E,  et  al.  Pulmonol.
The  mean  age  of  those  treated  with  Pirfenidone  was
71.04  ±  6.1  years  compared  to  78.33  ±  5.5  years  of  those
treated  with  Nintedanib.  The  median  age  of  patients  treated
with  Nintedanib  was  signiﬁcantly  higher  than  that  of  patients
d
T
p
po statistically  signiﬁcant  differences  among  the  groups  were
bserved  (p  >  0.05).
n  the  other  group  (p  <  0.0001)  due  to  the  Pirfenidone  group
nclusion  criteria  (in  Italy  only  patients  under  80  years  old
an  be  treated  with  this  drug  while  there  is  no  age  limit
or  Nintedanib).  As  expected,  there  was  a clear  prevalence
f  males  in  our  IPF  population  (80%)  with  no  difference
etween  groups  (Fig.  1).  Smoking  history  revealed  74%  of
mokers  in  the  Pirfenidone  group  and  52%  in  the  Nintedanib
roup.  Table  1  also  shows  that  the  most  common  symptoms
t  disease  onset  were  exertional  dyspnoea  and  dry  cough,
ith  no  difference  between  groups.  All  patients  manifested
ibasal  crackles  during  physical  examination,  and  clubbing
as  evident  in  35%  of  cases  (Table  1).
Fig.  2  indicates  lung  function  test  parameters  at  time
 and  after  6  and  12  months  in  the  population  of  IPF
atients  treated  with  Pirfenidone.  At  time  0,  FVC,  FEV1,
LCO  and  TLC  percentages  were  78.7  ±  16.9%  predicted
alues,  83.3  ±  16.5%  predicted,  51.2  ±  15.3%  predicted  and
8.7  ±  14.7%  predicted,  respectively.
Fig.  3  shows  lung  function  test  parameters  at  time
 and  after  6  and  12  months  in  the  population  of  IPF
atients  treated  with  Nintedanib.  At  time  0,  FVC,  FEV1,
LCO  and  TLC  percentages  were  80.9  ±  19.6%  predicted,
7  ±  19%  predicted,  47  ±  15%  predicted  and  66.3  ±  13%  pre-
icted,  respectively.  No  signiﬁcant  differences  in  FVC,  FEV1, 2018.  https://doi.org/10.1016/j.pulmoe.2018.06.003
LC  and  DLCO  percentages  were  found  at  time  0  between
atients  treated  with  the  two  drugs  (p  =  0.59,  p  =  0.37,
 =  0.21,  p  =  0.48,  respectively).
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Figure  3  Average  values  of  FVC,  FEV1,  TLC  and  DLCO  per-
centage  predicted  at  time  0  (n  =  30),  after  6  months  (n  =  16)
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an patients  treated  with  Nintedanib.  No  statistical  signiﬁcant
ifferences  among  these  groups  were  observed  (p  >  0.05).
At  6-month  follow-up,  FVC,  FEV1,  DLCO  and  TLC
ercentages  of  predicted  values  were  83  ±  17.3%  pre-
icted,  88.6  ±  18.3%  predicted,  50.7  ±  13.3%  predicted  and
1.3  ±  15%  predicted,  respectively,  in  patients  treated
ith  Pirfenidone,  and  78.3  ±  18%  predicted,  84.3  ±  17.8%
redicted,  47.6  ±  15.3%  predicted  and  67.15  ±  16%  pre-
icted,  respectively,  in  patients  treated  with  Nintedanib
Figs.  2  and  3).  Interestingly,  no  signiﬁcant  differences  in
VC,  FEV1,  DLCO  or  TLC  %  of  predicted  values  were  found
etween  patients  treated  with  Pirfenidone  and  Nintedanib
t  6-month  follow-up  (p  =  0.54,  p  =  0.38,  p  =  0.76,  p  =  0.31,
espectively).
Only  IPF  patients  treated  with  Pirfenidone  reached  12-
onth  follow-up  because  Nintedanib  was  approved  in  Italy
ore  recently  and  only  a  limited  number  of  patients  treated
ith  this  drug  had  completed  1  year  of  treatment  at  the
ime  of  writing.  At  12-month  follow-up,  FVC,  FEV1,  TLC  and
LCO  %  of  predicted  values  of  IPF  patients  treated  with
irfenidone  were  81.2  ±  20.7%  predicted,  86.7  ±  19.7%  pre-
icted,  70.2  ±  19.2%  predicted  and  46.7  ±  9.8%  predicted,
espectively.  No  statistical  difference  in  any  lung  func-
ion  test  parameter  was  observed  between  time  0  and  6
r  12  months  in  the  Pirfenidone  therapy  group  (p  >  0.05)
Figs.  2  and  3).
Pirfenidone  showed  a  good  tolerability  proﬁle  in  the
ajority  of  IPF  patients.  It  was  manageable  and  the  most
requent  side  effects  included  gastrointestinal  disorders  and
kin  reactions.  In  our  population  dyspepsia  and  nausea  were
he  most  frequent  adverse  event  occurring  in  35%  of  cases
ollowed  by  diarrhea  (28%  of  patients)  and  cutaneous  rash
19%  of  cases).  The  use  of  prokinetic  drugs  and  proton-pump
nhibitors  allowed  to  improve  gastrointestinal  side  effects
n  the  majority  of  patients  as  well  as  the  application  of  a
road-spectrum  sunscreen.  In  three  patients  the  rush  and
he  photosensitivity  were  severe  consequent  to  the  persis-
ent  sun  exposure  for  work  reasons.
Nintedanib  therapy  was  well  tolerated.  The  most  fre-
uent  side  effect  was  diarrohea  occurring  in  40%  of  patients
nd  requiring  in  18%  of  cases  a  premature  discontinuation.
reatment  interruption  was  necessary  only  in  5%  of  patients,Please  cite  this  article  in  press  as:  Bargagli  E,  et  al.  Pulmonol.
he  other  subjects  improved  after  dose  reduction  from  150
o  100  mg  twice  a  day.  8%  of  patients  treated  with  this
rug  presented  altered  liver  enzymes,  reversible  after  dose
eduction.  In  four  patients  the  elevation  of  aminotransferase
T
f
a PRESS
E.  Bargagli  et  al.
oncentrations  tended  to  persist  after  six  months  of  treat-
ent  and  liver  alteration  were  not  reversible  with  dose
odiﬁcation  and  discontinuation.  Both  these  patients  had
 persisting  mild  liver  dysfunction  secondary  to  lithiasis.
iscussion
afety  and  efﬁcacy  outcomes  of  Pirfenidone  and  Nintedanib
reatment  in  patients  with  IPF  are  available  from  many
nternational  clinical  trials.7,10--13 Very  little  data  is  cur-
ently  available  about  real-life  experience  with  antiﬁbrotic
rugs  in  IPF  patients.15--17 The  present  study  evaluated  the
ffectiveness  of  Pirfenidone  and  Nintedanib  therapy  in  a
opulation  of  IPF  patients  diagnosed  in  the  last  12  months
t  Florence  ILD  Referral  Centre.  This  observational  study
ffers  information  on  drug  effectiveness  in  the  real  clinical
etting  of  a  university  hospital,  but  can  only  partly  be  com-
ared  with  international  clinical  trials  and  it  has  the  limit
hat  did  not  show  12  months  follow-up  for  patients  treated
ith  Nintedanib.  As  expected,  there  was  a  high  prevalence
f  male  over  female  patients:  while  ILDs  associated  with
onnective  tissue  disorders  are  prevalent  in  women,  IPF  is
ypical  of  males  over  65  years  of  age.18 The  patients  in
he  Nintedanib  subgroup  were  older  than  those  in  the  Pir-
enidone  group,  because  in  Italy  IPF  patients  over  80  years
ld  can  only  be  treated  with  Nintedanib  and  not  with  Pir-
enidone.
In  line  with  the  literature,  all  patients  (100%)  presented
ibasal  crackles  and  restrictive  functional  deﬁcit  with  a  sig-
iﬁcant  reduction  in  DLCO  at  disease  onset.19,20 At  6-month
ollow-up  both  drugs  appeared  to  stabilize  the  spirometric
roﬁle  of  a  disease  typically  associated  with  deterioration
f  lung  function  in  the  period  of  a  few  months.  In  the
irfenidone  group,  stabilization  was  also  conﬁrmed  at  12-
onth  follow-up,  in  line  with  reports  on  the  literature.  In  our
eal-experience  study,  irrespective  of  baseline  functional
tatus,  treatment  with  the  two  drugs  was  associated  with
unctional  beneﬁts  that  were  similar  to  those  reported  in
linical  trials9 and  with  similar  rates  of  FVC  decline.  Stabi-
ization  of  lung  function  parameters  was  also  observed  in
he  older  population  of  patients  treated  with  Nintedanib.
This  preliminary  study  assessing  the  therapeutic  bene-
t  of  Pirfenidone  and  Nintedanib  in  an  Italian  cohort  of
PF  patients  revealed  a  stabilization  of  lung  function  test
arameters.  The  antiﬁbrotic  drugs  also  appeared  to  provide
unctional  stabilization  in  older  IPF/UIP  patients.
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